Cognitive Training for Attention-Deficit/Hyperactiviiy Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials
Samuele Cortese, Maite Ferrin, Daniel Brandeis, Jan Buitelaar, David Daley, Ralf W Dittmann, Martin Holtmann, Paramala Santosh, Jim Stevenson, Argyris Stringaris, Alessandro Zuddas, Edmund JS Sonuga-Barke
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | ELSEVIER SCIENCE INC | Published : 2015
Dr. Cortese has received royalties from Argon Healthcare Italia. Dr Ferrin has received economic support from the Instituto de Salud Carlos III, Consejeria de Salud Junta de Andalucia, Gobierno de Navarra (Beca Jeronimo Ayanz), and Fundacion Alicia Koplowitz. Prof. Buitelaar has served as a consultant to/advisory board member of/ and/or speaker for Janssen Cilag BV, Eli Lilly and Co., and Servier. Prof. Daley has provided educational talks for Eli Lilly and Co. and Shire; has attended an advisory board for Eli Lilly and Ca, has received support for educational travel from Eli Lilly and Co., Shire, and HP Pharma; and has received funding from Shire Prof. Dittmann has received compensation for serving as a consultant or speaker for, or he or the institution he works for have received research support or royalties from the companies or organizations indicated: the European Union (EU FP7 Programme), US National Institute of Mental Health (NIMH), German Federal Ministry of Health/Regulatory Agency (BMG/BfArM), German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), Volkswagen Foundation, Ferring, Janssen-Cilag, Eli Lilly and Co., Otsuka, Shire, and Theravance. He owns Eli Lilly and Co. stock. Prof. Holtmann has served as an advisor or consultant for Eli Lilly and Co., Novartis, Shire, and Bristol-Myers Squibb and has received conference attendance support or was paid for public speaking by AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Eli Lilly and Co., Medice, Neuroconn, Novartis, and Shire Dr. Santosh has received research funding from the EU (FP7 Programme) and the National Institute for Health Research (NIHR). He is also a director and shareholder of HealthTracker, Ltd., UK, and HighStreet Medical Dental, Gillingham, UK. Dr. Stringaris has received grant or research support from the Wellcome Trust, the NIHR, and the Department of Health UK. He has received royalties from Cambridge University Press for his book The Maudsley Reader in Phenomenological Psychiatry Prof. Zuddas has received research grants from the EU (FP7 Programme), Italian National Institute of Health, Sardinian Secretary of Public Health, Eli Lilly and Co., Shire, and Vifor and has served as speaker, adviser, or consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., Lundbeck, Schering-Plough, Shire, and Vifor He has been a member of Data Safety Monitoring Boards for Otsuka and Lundbeck Prof Sonuga-Barke has served on the speakers' board of Shire and Janssen-Cilag; has served as a consultant to Shire and NeuroTechnology Solutions, Ltd.; has received research support from Janssen-Cilag and Shire; has served on the advisory board of Shire and NeuroTechnology Solutions, Ltd.; and has received conference support from Shire Profs Brandeis and Stevenson report no biomedical financial interests or potential conflicts of interest.